Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
 
Working Life
Pharma, a career for life?
According to a recent survey, 70 per cent of pharma executives would like to remain in the industry throughout their working lives.
Approvals Action
Apotex and Generic Partners get busy
Apotex has been busy on the drugs register, preparing to compete in PBS markets worth close to $40 million, while Generic Partners is looking to compete with Pfizer.
PBS Snapshot
Full outcomes of July PBAC
The July PBAC meeting had an extensive agenda that included first-time submissions on major new drugs as well as some key re-submissions. Read all the results here.
Open Forum
Senators show Grattan up
The Grattan Institute has emerged from this week's Senate committee hearings with some dents in its reputation after its latest PBS price cut claims came under harsh scrutiny.
Pipeline Monitor
New US approvals in MS and insomnia
A first in class insomnia drug, a fortnightly injection for MS and a potential biosimilar competitor for Sanofi's Lantus have won approval from the FDA.